PET-CT

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma

Retrieved on: 
Monday, November 13, 2023
Uveal melanoma, Disease, Mum, OTCQB, Liver, Mortality, Patient, CMR, Kaplan–Meier estimator, Nivolumab, Ipilimumab, PET-CT, Springfield Armory M1A, Acceptability, Renewable energy, Pharmaceutical industry, Medical imaging

KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).

Key Points: 
  • KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).
  • mUM patients enrolled in this study received 1 or more cycles of PV-10 injection into 1 or more hepatic metastases.
  • Where indicated, standard of care immune checkpoint blockade (CB), as either monotherapy pembrolizumab or the combination of ipilimumab and nivolumab (IN), was also administered.
  • Dominic Rodrigues, Vice Chair of the Provectus’s Board of Directors, said, “Objective response is uncommon and complete metabolic response is rare in metastatic uveal melanoma.

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023
APOLLO, Sale, Antigen, D, Therapy, ODD, IND, Clinical trial, HMA, EMA, OTS, Patient, Research, U.S. FDA, FDA, SBIR, Committee, HLA, Trial of the century, Bone marrow, Drug discovery, AML, PET-CT, Orphan, Lymphoma, Pharmaceutical industry, Medical imaging

HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • “During the third quarter of 2023, we continued to diligently advance and execute our clinical objectives across our novel multiTAA-specific T cell pipeline,” commented Juan F. Vera, M.D., President and Chief Executive Officer of Marker Therapeutics.
  • Third Quarter 2023 Financial Highlights:
    Cash Position: Cash and cash equivalents of $17.5 million at September 30, 2023.
  • R&D Expenses: Research and development expenses were $2.0 million for the quarter ended September 30, 2023, compared to $3.6 million for the quarter ended September 30, 2022.
  • G&A Expenses: General and administrative expenses were $1.4 million for the quarter ended September 30, 2023, compared to $3.2 million for the quarter ended September 30, 2022.

Multimodal Imaging Market to Reach $7.9 Billion, Globally, by 2032 at 6.1% CAGR: Allied Market Research

Retrieved on: 
Wednesday, November 29, 2023
Conditional sentence, Prevalence, PET/CT, Incidence, Cardiology, Patient, PET-CT, Intelligence, Cancer, Diagnosis, Growth, Hospital, Medical imaging

PORTLAND, Ore., Nov. 29, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Multimodal Imaging Market by Technology (PET/CT Systems, PET/MR Systems, SPECT/CT Systems, and Others), Application, (Brain &Neurology, Cardiology, Oncology, Ophthalmology, and Others), and End User, (Hospitals, Diagnostic imaging centers, and others.): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global multimodal imaging industry generated $4.4 billion in 2022, and is anticipated to generate $7.9 billion by 2032, witnessing a CAGR of 6.1% from 2023 to 2032.

Key Points: 
  • This could affect patients' ability to access and afford multimodal imaging, potentially leading to decreased demand for imaging systems.
  • This results in delayed or scaled-down investments in expensive multimodal imaging technologies.
  • This could boost the need for specific types of multimodal imaging that is experiencing a moderate positive impact from the global recession.
  • Rise in awareness about early diagnosis and treatment, increase in prevalence of chronic diseases such as cancer, and growing demand for advanced imaging systems, is expected to drive the growth of the multimodal imaging market.

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
FDA, DSM-IV codes, Translation, Fred Hutchinson Cancer Research Center, Infrared spectroscopy correlation table, Bone marrow, University of Washington, Disclosure, Chronic lymphocytic leukemia, Waldenström, Society, PET-CT, Disease, Cancer, Follicular lymphoma, Mustang, University, DL, NHL, Safety, Patient, Investigational New Drug, Associate, American Society of Hematology, HCL, Lymphoma, Pharmaceutical industry, WM

MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).

Key Points: 
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).
  • All patients displayed MB-106 expansion, with peak levels between 7-14 days post-infusion, and CAR-T cell persistence is ongoing at 6 months.
  • From a safety perspective, 3 patients experienced Grade 1 cytokine release syndrome and no occurrences of immune effector cell-associated neurotoxicity syndrome were reported.
  • Dose-limiting toxicities (“DLT”) were monitored through day 28, and no DLTs were observed at DL1.

5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Yale School of Medicine, Neoplasm, Patient, Survival, NYSE, ESMO, III, Life, Hope, Lymph, Physician, Congress, Head, European Society for Medical Oncology, Multimedia, Senior, Disease, Risk, Cis, Pembrolizumab, Immunotherapy, University, Consultant, LI, Cancer, Randomized controlled trial, PET-CT, Diagnosis, Death, Regulatory affairs, Pharmaceutical industry

CEL-SCI presented the data for the first time at the European Society for Medical Oncology (ESMO) Congress in Spain on October 22, 2023.

Key Points: 
  • CEL-SCI presented the data for the first time at the European Society for Medical Oncology (ESMO) Congress in Spain on October 22, 2023.
  • The target population is estimated to cover ~145,000 advanced primary head and neck cancer patients globally per year.
  • Second, the Multikine target population can now be readily identified upon diagnosis, prior to surgery, using tests that physicians routinely use in cancer screenings.
  • CEL-SCI is not aware of any head and neck cancer therapy that has shown such a large 5-year survival benefit.

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023
Pheochromocytoma, DOTATATE, NETS, MBBS, EANM, TAT, Thyroid cancer, Quality of life, DNB, Nuclear medicine, Paraganglioma, PET-CT, Șaeș, Non-small-cell lung cancer, MDS, Hair, Targeted molecular therapy for neuroblastoma, CATX, Patient, Standard of care, Syndrome, Molina Healthcare, FMRI, European Association for the Study of the Liver, Therapy, NYSE, PRRT, Meningioma, Safety, Fatigue, Pharmaceutical industry

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Retrieved on: 
Monday, September 11, 2023
Lymphoma, Marker, Press release, B-cell lymphoma, DLBCL, Clinical trial, PET-CT, APOLLO, Service provider, CAR, Patient, Observation, Therapy, Safety, Bone marrow, Vaccine, Pharmaceutical industry

HOUSTON, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Today Marker is announcing the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter APOLLO clinical trial. The APOLLO trial is investigating the safety and efficacy of MT-601 for the treatment of patients with lymphoma who have either failed or are ineligible to receive anti-CD19 CAR T cell therapy.

Key Points: 
  • After relapse following anti-CD19 CAR T cell therapy, the participant was treated with 2 doses of MT-601 at the 200 million cell dose level without prior lymphodepletion.
  • Eight weeks after the 2nd infusion of MT-601, the participant demonstrated complete metabolic response based on PET-CT scans.
  • “We are delighted to announce that the first study participant treated in the APOLLO trial achieved a complete response after treatment with MT-601,” said Monic Stuart, M.D., Chief Medical Officer of Marker Therapeutics.
  • “Our APOLLO trial is an important area for MT-601 assessment, as up to 60% of patients treated with anti-CD19 CAR T therapies relapse within one year.

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, August 28, 2023
Neuroblastoma, Abstract, MBBS, Metastasis, EANM, Glomus tumor, Targeted molecular therapy for neuroblastoma, MBA, DNB, Nuclear medicine, PET-CT, Perspective, European Association of Nuclear Medicine, CATX, MD, Patient, Molina Healthcare, FMRI, Cancer, Therapy, NYSE, Targeted alpha-particle therapy, Pharmaceutical industry, Safety, IOWA

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).

Key Points: 
  • RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).
  • “Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • “We are particularly excited about the early clinical results from 212Pb-VMT-α-NET in patients suffering from different types of difficult-to-treat neuroendocrine tumors.
  • The data showed that fractionated doses of [212Pb]VMT-α-NET provided greater benefit than single dose administration of [212Pb]VMT-α-NET.

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Retrieved on: 
Wednesday, August 16, 2023
Lymphoma, International Workshop on Lung Health, Waldenström macroglobulinemia, US Foods, University, CD19, Chronic lymphocytic leukemia, Follicular lymphoma, CRS, Fred Hutchinson Cancer Research Center, University of Washington, Clinical trial, Immunoglobulin M, Bone marrow, NHL, PET-CT, Immunotherapy, Associate, Translation, Regenerative medicine, WM, Patient, Cancer, CR, Orphan, Diagnosis, Trial of the century, Hairy cell leukemia, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mustang, DSM-IV codes, Food, Safety, Disease, Grade 2, Medical imaging, Vaccine, Pharmaceutical industry

WORCESTER, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia (“CLL”), demonstrating clinical responses as well as safety and efficacy consistent with the ongoing Phase 1/2 clinical trial taking place at Fred Hutchinson Cancer Center (“Fred Hutch”).

Key Points: 
  • The multicenter data also show persistence of CAR-T cells at 6+ months and favorable safety data with only Grade 1 cytokine release syndrome (“CRS”) reported to date.
  • Additionally, the data from the ongoing clinical trial at Fred Hutch continue to demonstrate a high rate of complete and durable responses.”
    Dr. Shadman also presented data from the ongoing Fred Hutch Phase 1/2 clinical trial, specific to two B-NHL cohorts, follicular lymphoma (“FL”) and WM.
  • Furthermore, Mustang anticipates requesting regenerative medicine advanced therapy (RMAT) designation for WM from the FDA in 2024.
  • Finally, data from the Fred Hutch clinical trial also support the potential of MB-106 to be administered as outpatient therapy and provide a best-in-class immunotherapy option for patients treated previously with CD19-directed CAR-T cell therapy.

CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results

Retrieved on: 
Friday, August 11, 2023
Research, Surgery, Clinical Trials, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Condition, HPP, Neoplasm, Food, Policy, Survival, SCCHN, Head, American Head, PET-CT, Radiation therapy, Congress, NYSE, Patient, Physician, Data, NOCC, FDA, Health Canada, PD-L1, Pembrolizumab, Conference, Pharmaceutical industry, Medical imaging

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments.
  • Clinical and Corporate Developments this quarter include:
    CEL-SCI had a productive pre-submission meeting with Canada’s regulator, Health Canada, to determine the best regulatory path toward market approval.
  • CEL-SCI is preparing an application for the NOCC approval as suggested and plans to file it by early next year.
  • CEL-SCI reported a loss per share for the quarter ending June 30, 2023 of $0.19 versus a loss of $0.23 for the quarter of June 30, 2022.